Biotech Startups

Empress provides drug discovery teams with an industrialized Perturb-seq platform that combines CRISPR-based single-cell functional genomics, chemoproteomics, and multi-omics with causal machine learning to identify what drives activity, efficacy, and risk. It serves pharmaceutical and biotech R&D teams seeking mechanistic understanding of drug targets.

1 investor

Emtora Biosciences is a clinical-stage life science company developing eRapa, a novel formulation of rapamycin, to prevent the onset and recurrence of cancer. Its lead program, Serenta (eRapa), is in a Phase 3 trial evaluating safety and efficacy in patients diagnosed with familial adenomatous polyposis (FAP).

1 investor

Emulsi develops NanoLIPID™, a natural lipid technology that self-assembles into nano-structures for encapsulating active pharmaceutical ingredients, nutraceuticals, and bioactive compounds. The platform targets oral drug delivery, cosmetics, and nutraceutical applications.

1 investor

EmVenio runs decentralized clinical research through in-home patient visits, community-based research sites, and patient navigation services, helping trial sponsors and CROs reach underrepresented populations. It supports clinical trial recruitment, retention, and data capture across more than 90 countries.

1 investor

Enable Biosciences develops ultrasensitive antibody detection assays based on its Antibody Detection by Agglutination-PCR (ADAP) technology for diagnosing conditions including type 1 diabetes, celiac disease, food allergy, Lyme disease, and Zika/dengue. It offers testing services, custom assay development, and automated workstations for research and clinical diagnostics laboratories.

1 investor

EncepHeal develops small-molecule medications to treat substance use disorders, with a lead therapeutic targeting stimulant addiction such as cocaine and methamphetamine. Its compounds act as atypical/allosteric modulators of the dopamine transporter, developed with partners at the NIH and Wake Forest.

1 investor

Endeavor BioMedicines is a biopharmaceutical company developing medicines aimed at treating patients with serious, intractable diseases, with the goal of altering disease progression rather than only slowing it.

1 investor

Endevica (Kalohexis) is a clinical-stage biotechnology company developing peptidomimetic melanocortin drug candidates. Its pipeline targets metabolic disorders such as obesity and cancer cachexia.

1 investor

Endlyz develops small-molecule disease-modifying therapeutics targeting the ATP13A2 and ATP10B lysosomal transporters to restore endo-lysosomal function and counter neurodegeneration. Its initial focus is genetic subsets of Parkinson's disease, with plans to expand into sporadic Parkinson's and other dementias.

1 investor

Novartis is a pharmaceutical company developing breakthrough medicines across therapeutic areas including oncology and cardiovascular disease.

1 investor

Endolipid Therapeutics is a biotech developing SHBG-mimicking peptides aimed at reducing ectopic fat accumulation to treat conditions such as fatty liver disease and NASH, as well as cellulite. Its work spans therapeutic and dermocosmetic applications.

1 investor

EndoProTech develops anti-inflammatory liposomes designed to modify the composition of cell plasma membranes and reduce microvascular dysfunction following ischemia/reperfusion injury. Its research targets reducing infarct size after myocardial infarction while preserving tissue viability and shortening recovery time.

1 investor

EndoStim develops a neurostimulation medical device system for treating drug-resistant gastroesophageal reflux disease (GERD) by restoring esophageal function while preserving normal anatomy.

1 investor

EndoVia develops a precision oncology platform that combines experimental biology with computational modeling to match cannabinoid-based cancer treatments to individual patients. It maps cannabinoid and extract libraries against biological targets, uses subtype-specific tumor models and multi-omics profiling, and builds predictive network and digital-twin models to guide therapeutic development.

1 investor

Enemsa Pharma is a biopharmaceutical company developing neuroprotective, disease-modifying therapies aimed at restoring cellular homeostasis through proteostasis modulation, mitophagy enhancement and mitochondrial protection. Its treatments target patients with neurodegenerative and neuromuscular disorders such as ALS and CMT, led by its platform asset Icerguastat.

1 investor

1 investor

Early-stage oncology company developing a breakthrough siRNA platform to target undruggable cancer pathways.

1 investor

Engimmune develops soluble TCR therapeutic candidates using AI-guided innovation and protein engineering for oncology and immunotherapy applications. The company was founded by veteran biotherapeutics developers and focuses on unlocking therapeutic potential through its differentiated technology platform.

1 investor

Engram Biosciences is an applied neurobiology research lab that builds tools and models to aggregate human brain data at scale, operating a 10,000 sq ft automated lab. It is a research-driven company staffed by researchers and engineers working in neuroscience and biotechnology.

1 investor

Enjamb develops an agentic AI platform for biopharma R&D teams that automates drug discovery, trial execution, and regulatory filings. The platform integrates with existing systems to support programs from early discovery through FDA approval.

1 investor

Enlivex is a Nasdaq-listed clinical-stage biotech developing Allocetra, a macrophage reprogramming immunotherapy targeting age-related knee osteoarthritis to restore mobility and function in aging populations. The company also runs a treasury strategy anchored in RAIN, a prediction markets protocol on Arbitrum, offering public-market exposure to prediction market infrastructure.

1 investor

EnnoDC is a clinical-stage biotech developing a class of immunotherapy antibodies called Dendritic Cell (DC) engagers, which prime antigens and activate dendritic cells to trigger an immune response against cancer and viral infections. Its pipeline includes five antibody candidates, with programs in HPV16+ oropharyngeal and prostate cancer following early clinical work in HIV and COVID-19.

1 investor

Enodia Therapeutics develops small-molecule therapies that target protein degradation at the point of synthesis using a machine learning-enabled platform. The company serves the therapeutic development market with its targeted protein degradation approach.

1 investor

EnrollNow is a software platform for managing participant screening, enrollment, and study management across academic, clinical, and independent research programs. Originating from a University of Michigan research lab and licensed through Ripple Science Corporation, it is used by research teams globally and is HIPAA-compliant and SOC 2 certified.

1 investor